StockData
Entrada Therapeutics, Inc. logo

Entrada Therapeutics, Inc. (TRDA) stock

TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$5.00−0.09 (-1.77%)

Close on Nov 16, 2026Market cap $194.68MP/E –Yield –

Entrada Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Entrada Therapeutics's pe ratio was 7.3× on Jul 31, 2025, against 27.9× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Jul 31, 20257.3×−3.9
2024Dec 31, 202411.2×–

More Entrada Therapeutics figures

See a number that looks wrong?